Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00738023 · ClinicalTrials.gov registry record · Phase 4
Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT00738023 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 36 participants.
The verdict
NCT00738023, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
Insulin resistance has been implicated as the central pathogenetic feature of cardiovascular risk factor cluster that includes hypertension, impaired glucose tolerance, diabetes, dyslipidemia, and hemostatic disorders. Recent evidence suggests that increased levels of free fatty acids (FFA) in obese subjects is a leading candidate in the pathogenesis of insulin resistance (1-4). In our preliminary studies on the effect of FFA on insulin secretion and action (lipotoxicity), we have observed that the infusion of Intralipid/heparin to increase FFA \~ four-fold-baseline levels for 48 hours results in a significant and reproducible raise in systolic and diastolic blood pressure (BP) in obese African American subjects with and without diabetes. The increase in blood pressure is apparent after 12 hours of infusion, reaching a peak increment of 32 mm Hg in systolic and 14 mm Hg in diastolic pressure at 24 hours. These preliminary findings indicate that, in addition to the well-known effect on insulin resistance, sustained elevation of FFA results in the development of an acute metabolic syndrome.
Interventions
- DRUG Rosiglitazone
- DRUG Intralipid 20%
- DRUG Normal saline 0.9%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-03 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00738023
The ClinicalTrials.gov registry entry for NCT00738023 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rosiglitazone is the first listed.
NCT00738023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00738023 about?
NCT00738023 is a clinical study titled "Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes". Insulin resistance has been implicated as the central pathogenetic feature of cardiovascular risk factor cluster that includes hypertension, impaired glucose tolerance, diabetes, dyslipidemia, and hemostatic disorders. Recent evidence suggests that increased levels of free fatty acids (FFA) in obese...
What is the current status of trial NCT00738023?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2004-03. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00738023?
The interventions under investigation include: Rosiglitazone (DRUG), Intralipid 20% (DRUG), Normal saline 0.9% (DRUG).
Who is sponsoring clinical trial NCT00738023?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.